Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 25 (oversold) · MACD below its signal · 4% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.1M | 0.00% | 67.30K | −3.0% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CTNM trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 7, 2026 | Stengone Carmine NChief Executive Officer | Sale at price 16.46 per share. | 2.5K | $41.14K |
| Sep 7, 2026 | Stengone Carmine NChief Executive Officer | Conversion of Exercise of derivative security at price 1.01 per share. | 2.5K | $2.52K |
| Aug 2, 2026 | Stengone Carmine NChief Executive Officer | Sale at price 16.01 per share. | 2.5K | $40.03K |
| Aug 2, 2026 | Stengone Carmine NChief Executive Officer | Conversion of Exercise of derivative security at price 1.01 per share. | 2.5K | $2.52K |
| Jul 8, 2026 | Lorrain Daniel S.Officer | Sale at price 16.00 per share. | 1K | $16.64K |
| Jul 8, 2026 | Lorrain Daniel S.Officer | Conversion of Exercise of derivative security at price 1.01 per share. | 1K | $1.05K |
| Jul 7, 2026 | Stengone Carmine NChief Executive Officer | Sale at price 16.00 per share. | 2.5K | $40.00K |
| Jul 7, 2026 | Stengone Carmine NChief Executive Officer | Conversion of Exercise of derivative security at price 1.01 per share. | 2.5K | $2.52K |
| Jun 30, 2026 | Lorrain Daniel S.Officer | Sale at price 15.67 - 16.24 per share. | 37.2K | $594.58K |
| Jun 30, 2026 | Lorrain Daniel S.Officer | Conversion of Exercise of derivative security at price 1.01 per share. | 33K | $33.34K |
| Jun 29, 2026 | Stengone Carmine NChief Executive Officer | Sale at price 16.01 per share. | 10K | $160.08K |
| Jun 29, 2026 | Watkins Timothy R.Officer | Sale at price 16.02 per share. | 10.8K | $173.59K |
| Jun 29, 2026 | Stengone Carmine NChief Executive Officer | Conversion of Exercise of derivative security at price 1.01 - 1.26 per share. | 10K | $10.72K |
| Jun 29, 2026 | Watkins Timothy R.Officer | Conversion of Exercise of derivative security at price 4.50 per share. | 10.8K | $48.75K |
| May 31, 2026 | Lorrain Daniel S.Officer | Sale at price 13.16 per share. | 4.2K | $54.86K |
| Apr 30, 2026 | Lorrain Daniel S.Officer | Sale at price 13.06 - 13.84 per share. | 4.2K | $54.69K |
| Apr 5, 2026 | Lorrain Daniel S.Officer | Sale at price 13.43 per share. | 4.2K | $56.01K |
| Mar 1, 2026 | Lorrain Daniel S.Officer | Sale at price 15.01 per share. | 4.2K | $62.59K |
| Mar 1, 2026 | Watkins Timothy R.Officer | Sale at price 15.02 per share. | 3.6K | $54.22K |
| Mar 1, 2026 | Watkins Timothy R.Officer | Conversion of Exercise of derivative security at price 4.50 per share. | 3.6K | $16.25K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 24.8 | 7.6 | -14.9 | -1.8 | 5.2 | 21.5 | -5.5 | 4.8 | -17.4 | -37.3 | −26.3% | ||
| 2025 | -33.2 | -28.1 | -0.9 | -41.1 | -10.9 | 8.5 | 48.6 | 77.1 | 12.4 | -6.3 | 0.5 | 3.3 | −22.0% |
| 2024 | -1.8 | 14.9 | 13.9 | -2.8 | -1.8 | -12.4 | -11.0 | -1.7 | −6.1% |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Buy / hold / sell counts